Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study.

Cell Rep Med 2020 Aug 5;1(5):100073. Epub 2020 Aug 5.

Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands.

Bacille Calmette-Guérin (BCG) induces long-term boosting of innate immunity, termed trained immunity, and decreases susceptibility to respiratory tract infections. BCG vaccination trials for reducing SARS-CoV-2 infection are underway, but concerns have been raised regarding the potential harm of strong innate immune responses. To investigate the safety of BCG vaccination, we retrospectively assessed coronavirus disease 2019 (COVID-19) and related symptoms in three cohorts of healthy volunteers who either received BCG in the last 5 years or did not. BCG vaccination is not associated with increased incidence of symptoms during the COVID-19 outbreak in the Netherlands. Our data suggest that BCG vaccination might be associated with a decrease in the incidence of sickness during the COVID-19 pandemic (adjusted odds ratio [AOR] 0.58, p < 0.05), and lower incidence of extreme fatigue. In conclusion, recent BCG vaccination is safe, and large randomized trials are needed to reveal if BCG reduces the incidence and/or severity of SARS-CoV-2 infection.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xcrm.2020.100073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405881PMC
August 2020

Publication Analysis

Top Keywords

bcg vaccination
16
covid-19 symptoms
8
vaccination associated
8
bcg
7
assessed coronavirus
4
retrospectively assessed
4
vaccination retrospectively
4
safety bcg
4
coronavirus disease
4
disease 2019
4
symptoms three
4
2019 covid-19
4
investigate safety
4
three cohorts
4
cohorts healthy
4
immune responses
4
underway concerns
4
infection underway
4
sars-cov-2 infection
4
reducing sars-cov-2
4

Similar Publications